Herbert Loong/LinkedIn
Jun 8, 2025, 08:38
Herbert Loong: The Role of Selective RET Inhibitors in the Management of NSCLC
Herbert Loong, Chair-Elect of the International Affairs Committee and the Track Leader for Sarcoma (2023) at the American Society of Clinical Oncology (ASCO), shared a post on LinkedIn:
“Ending a whirlwind trip to Manila Philippines to discuss with thoracic oncologists on the role of selective RET inhibitors in the management of NSCLC and the relevance and importance of efficient molecular testing.
Thanks Herdee Gloriane C. Luna, Roselle De Guzman and other Filipino colleagues for your wonderful hospitality and interactive discussions. :)”
Herbert Loong reflected on discussions held in Manila regarding selective RET inhibitors in NSCLC treatment and the critical role of effective molecular testing.
More posts featuring Herbert Loong.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 8, 2025, 08:03